We analyzed this claim: is it true that
ArriVent BioPharma's oral medicine firmonertinib kept lung cancer from progressing significantly longer than chemotherapy in an advanced Phase 3 study?
The international trial missed its primary goal because the extra time without tumor growth was not statistically meaningful, despite shrinking more tumors than chemotherapy.
ArriVent lung cancer pill misses main trial goal
An experimental daily medicine failed to prove it stops a rare lung tumor longer than standard chemotherapy.
In a nutshell
ArriVent BioPharma and Shanghai Allist Pharmaceuticals suffered a clinical defeat when their daily lung cancer pill failed to outperform chemotherapy by a statistically meaningful margin. While the experimental drug shrank more tumors and caused fewer serious side effects than standard chemotherapy, it did not significantly prolong the time patients lived without their cancer worsening. The outcome makes quick regulatory approval for newly diagnosed patients doubtful and erased substantial market value across both companies.
Highlights
- The high 240 mg dose held cancer growth for 11.0 months compared with 9.5 months on chemotherapy, missing the statistical threshold for success.
- The experimental pill shrank tumors in 60% of high-dose patients versus 33% on standard chemotherapy.
- Serious treatment-related side effects occurred in 26% of high-dose patients compared with 40% receiving chemotherapy.
- ArriVent shares fell 46.98% in New York, while Shanghai Allist shares dropped by the 20% daily limit in Shanghai.
Months without tumor progression by treatment
months- A comparison of the median months patients lived without cancer growth across the three trial treatment groups.
- Progression-free survival — The length of time patients live with cancer without the disease worsening
- The 1.5-month difference between the top dose and chemotherapy fell short of statistical proof, delaying a new pill for patients.
Patient outcomes across trial treatment groups
| Treatment group | Tumor response rate | Severe side effect rate |
|---|---|---|
| Firmonertinib 240 mg | 60% | 26% |
| Firmonertinib 160 mg | 35% | 22% |
| Chemotherapy | 33% | 40% |
- A comparison of tumor shrinkage rates and serious treatment-related adverse event rates across all three study arms.
- The pill shrank more tumors with fewer severe side effects, showing biological activity even though it missed the primary survival goal.
From the Editor’s Diary
Shrinking a tumor does not always translate into a lasting survival advantage in clinical trials. Even when a targeted medicine is easier to take and safer than chemotherapy, health regulators require clear mathematical proof that it keeps disease under control longer before changing standard medical practice.
Who's involved
ArriVent BioPharma
American clinical-stage drugmaker based in Pennsylvania that tests medicines internationally
goal → Win regulatory approval for its daily cancer pill abroad and build a lasting business beyond China
Shanghai Allist Pharmaceuticals
Chinese pharmaceutical developer that created the pill and sells it domestically
goal → Defend the commercial value of its approved drug while expanding into new medical uses
Bing Yao
Chief executive of ArriVent BioPharma
goal → Chart a workable plan for the drug after the failed trial and reassure investors and patients
Du Jinhao
Chairman and controlling shareholder of Shanghai Allist Pharmaceuticals
goal → Stabilize market confidence by proposing a company-funded repurchase of its shares
U.S. Food and Drug Administration
American health regulator that decides if new drugs are safe and effective
goal → Protect patients by approving medicines only when strong clinical proof demonstrates their benefits
Patients with EGFR exon 20 insertion-mutant lung cancer
People with an uncommon genetic form of advanced lung cancer
goal → Gain access to convenient treatments that keep tumors from spreading while protecting daily comfort
In short
Patients with a rare, aggressive form of lung cancer will have to wait longer for an easier daily pill after a late-stage international study missed its main goal. The setback makes regulatory approval for this initial treatment unlikely anytime soon, leaving standard hospital chemotherapy as the foundation of first-line care. Whether the drug can find another path forward remains uncertain until researchers finish examining the full trial data.
ArriVent BioPharma said its oral drug firmonertinib kept tumors from growing for a median of 11.0 months at the top dose, compared with 9.5 months on chemotherapy. While the pill delayed tumor growth by an extra month and a half and shrank more tumors, the mathematical margin of difference was not large enough to rule out chance under the study's rules.
The disappointment quickly erased market value for the drugmakers across two continents. ArriVent shares fell nearly 47% in New York, while its partner Shanghai Allist Pharmaceuticals dropped 20% in Shanghai. The medicine remains approved in China for other lung cancer uses, but this trial closes off a quick route to becoming a first-choice global therapy.
How it unfolded
A partnership forms to take a Chinese cancer pill global
The effort began five years ago when ArriVent agreed to develop Allist's experimental lung cancer medicine outside Greater China. The deal committed ArriVent to a $40 million upfront payment, with up to $765 million in potential milestone payments as work progressed. ArriVent secured up to $150 million in launch financing to fund the global clinical program.
Promising early results lead to an ambitious international test
The partners launched an advanced Phase 3 trial called FURVENT to test whether their pill could beat chemotherapy in newly diagnosed patients. Early evidence from a small preliminary study showed tumors shrank in 78.6% of untreated patients on the highest dose. Yet the competitive landscape soon changed when American regulators approved an intravenous combination from Johnson & Johnson for the same rare tumor type.
Patient enrollment finishes while final results face delays
ArriVent completed enrollment in early 2025 and initially anticipated final trial results by early 2026. Allist gained Chinese approval in February 2026 to use the pill in patients whose cancer had worsened after chemotherapy, but that did not resolve the bigger question of first-line use. The expected reporting date for the global study gradually slipped from mid-2026 into the second half of the year.
The main study goal falls short despite tumor shrinkage
ArriVent announced that the trial missed its primary goal of proving a clear delay in cancer progression under independent review. The high 240 mg dose kept cancer stable for 11.0 months, compared with 9.5 months for chemotherapy and 8.4 months for a lower 160 mg dose. Although the higher dose shrank tumors in 60% of patients and showed fewer severe side effects, the narrow survival margin failed the statistical test, sending ArriVent shares down nearly 47%.
Market losses spread to China as partners weigh next steps
The trial failure prompted Wall Street analysts to lower price targets for ArriVent, while Allist confirmed the news to Chinese regulators. Allist reported spending approximately 70.82 million yuan on domestic trial work and saw its stock plunge 20% in Shanghai trading. Allist's chairman proposed repurchasing up to 200 million yuan in shares to restore confidence as both companies began reviewing the complete data.
Where things stand
The Phase 3 trial did not succeed on its primary goal, making an immediate global approval for newly diagnosed patients unlikely. The drug remains commercially available in China for patients who already tried chemotherapy or who carry other specific mutations.
The partners are evaluating the full clinical data before announcing whether they will abandon this use or seek alternative regulatory avenues. With existing alternatives already approved by health authorities, the companies must decide whether to continue testing the pill or redirect capital to other experimental programs.